PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology

Executive Summary

• Australian Patent No. AU2020212659 for “A Cyclic Peptide” has been granted, covering PreveCeutical’s pain‑therapy program.
• The patent provides exclusivity in Australia until January 2040 and is jointly owned with the University of Queensland.
• The filing is part of a broader global IP strategy with corresponding applications pending in the United States, Europe, and Canada.

Key Details

• Patent number: AU2020212659 – titled “A Cyclic Peptide.”
• Scope: Protection for novel cyclized peptides that are analogues of dynorphin, intended for pain relief with reduced opioid‑related adverse effects.
• Ownership: Jointly held by PreveCeutical Medical Inc. and the University of Queensland.
• Geographic coverage: Exclusivity in Australia until January 2040 (subject to maintenance fees).
• Global strategy: Corresponding patent applications pending in the United States, Europe, and Canada, expanding the company’s IP portfolio.
• Therapeutic focus: Next‑generation peptide‑based analgesics designed for enhanced stability, receptor selectivity, and improved patient outcomes in acute and chronic pain management.
• CEO comment (Stephen Van Deventer): Emphasized the patent as a “significant achievement” that strengthens PreveCeutical’s market position and supports its long‑term commercialization strategy.

Notable Quotes

“The grant of this patent is a significant achievement for PreveCeutical and underscores our commitment to pioneering innovative solutions for pain management. This intellectual property strengthens our position in a global market seeking safer alternatives to opioids and supports our long‑term commercialization strategy.” – Stephen Van Deventer, CEO

Materiality Assessment: Non‑Material – Positive (the announcement is materially positive for IP positioning but does not yet translate into quantifiable financial impact).